Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Systemic and IA Melphalan in Retinoblastoma
NCT02116959Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Jul 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of melphalan in retinoblastoma (Rb), sponsored by University of California, San Francisco. Primary endpoints: Adverse Event evaluation up to 2 years and Dose-Limiting Toxicity up to 2 years. Started Jul 2014; status: terminated.
02
Drugs
melphalan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT02116959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116959.